GlassScriptPhysician profile
Thamilvani Thiruvasahar
NPI 1790948768
$18,376.36
in general payments reported to CMS, 2019-2025
39 companies · $3,184 in 2025
The $3,184 reported for 2025 was more than what 78% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $1,528 · 2021: $1,585 · 2022: $1,699 · 2023: $3,862 · 2024: $5,146 · 2025: $3,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Honoraria: $1,200 · Education: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,403.73 |
| Honoraria | $1,200.00 |
| Education | $588.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $4,357.31 | 2019-2025 | Evenity, Tavneos, Prolia |
| Abbvie INC. | $2,362.11 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,658.25 | 2019-2025 | Tremfya, Simponi Aria |
| Janssen Scientific Affairs, LLC | $1,445.87 | 2019-2024 | Tremfya |
| Chiesi USA, INC. | $1,200.00 | 2024 | Juxtapid |
| Genzyme Corporation | $781.68 | 2021-2025 | |
| Pfizer INC. | $755.20 | 2019-2025 | |
| Glaxosmithkline, LLC. | $671.67 | 2020-2025 | Benlysta, Nucala |
| Mallinckrodt Hospital Products INC. | $646.30 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $599.42 | 2020-2025 | |
| Horizon Therapeutics Plc | $584.59 | 2020-2023 | Krystexxa |
| Ucb, INC. | $546.93 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $497.51 | 2019-2025 | Taltz, Zepbound |
| Astrazeneca Pharmaceuticals LP | $396.53 | 2021-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.93 | 2020-2025 | Ofev, Cyltezo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thamilvani Thiruvasahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.